TYRA earnings: next report 2026-08-13, real EPS beat/miss history, analyst consensus Buy, P/E -14.03. Updated 2026-07-23.
Tyra Biosciences (TYRA) Research Hub
Tyra Biosciences (TYRA) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 22.03 USD (+0.09%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -14.03, market cap 1.86B. This hub links to the full technical, earnings and options research available for TYRA.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 22.03 USD (+0.09%) |
| 52-week range | 18.66 USD – 33.43 USD |
| Trend regime | Range |
| 14-day RSI | 37.3 (Bearish) |
| Trailing P/E | -14.03 |
| Market cap | 1.86B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-13 |
Available research for TYRA
Covered Call on TYRA: how it works, illustrative setup around the real 22.03 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on TYRA: how it works, illustrative setup around the real 22.03 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on TYRA: how it works, illustrative setup around the real 22.03 USD price, max profit/loss, breakeven and when to use it. Educational.
TYRA technical analysis: range, last 22.03 USD, RSI 37.3, 52w range 18.66 USD–33.43 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is TYRA in?
Tyra Biosciences (TYRA) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is TYRA in an uptrend or downtrend?
As of 2026-09-11, TYRA is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is TYRA's trailing P/E ratio?
TYRA's trailing P/E is -14.03, with a market cap of 1.86B. See the earnings research page for full valuation detail.
When does TYRA next report earnings?
TYRA is next scheduled to report earnings on 2026-08-13, with a consensus EPS estimate of -0.67 USD.